FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086659384> ?p ?o ?g. }

• W2086659384 endingPage "23097" @default.
• W2086659384 startingPage "23093" @default.
• W2086659384 abstract "Extracellular nucleotides regulate function in many cell types via activation of multiple P2-purinergic receptor subtypes. However, it has been difficult to define which individual subtypes mediate responses to the physiological agonist ATP. We report a novel means to determine this by exploiting the differential activation of an autocrine/paracrine signaling pathway. We used Madin-Darby canine kidney epithelial cells (MDCK-D1) and assessed the regulation of cAMP formation by nucleotides. We found that ATP, 2-methylthio-ATP (MT-ATP) and UTP increase cAMP production. The cyclooxygenase inhibitor indomethacin completely inhibited UTP-stimulated, did not inhibit MT-ATP-stimulated, and only partially blocked ATP-stimulated cAMP formation. In parallel studies, ATP and UTP but not MT-ATP stimulated prostaglandin production. By pretreating cells with indomethacin to eliminate the P2Y2/prostaglandin component of cAMP formation, we could assess the indomethacin-insensitive P2 receptor component. Under these conditions, ATP displayed a ten-fold lower potency for stimulation of cAMP formation compared with untreated cells. These data indicate that ATP preferentially activates P2Y2 relative to other P2 receptors in MDCK-D1 cells (P2Y1 and P2Y11, as shown by reverse transcriptase polymerase chain reaction) and that P2Y2 receptor activation is the principal means by which ATP increases cAMP formation in these cells. Blockade of autocrine/paracrine signaling can aid in dissecting the contribution of multiple receptor subtypes activated by an agonist. Extracellular nucleotides regulate function in many cell types via activation of multiple P2-purinergic receptor subtypes. However, it has been difficult to define which individual subtypes mediate responses to the physiological agonist ATP. We report a novel means to determine this by exploiting the differential activation of an autocrine/paracrine signaling pathway. We used Madin-Darby canine kidney epithelial cells (MDCK-D1) and assessed the regulation of cAMP formation by nucleotides. We found that ATP, 2-methylthio-ATP (MT-ATP) and UTP increase cAMP production. The cyclooxygenase inhibitor indomethacin completely inhibited UTP-stimulated, did not inhibit MT-ATP-stimulated, and only partially blocked ATP-stimulated cAMP formation. In parallel studies, ATP and UTP but not MT-ATP stimulated prostaglandin production. By pretreating cells with indomethacin to eliminate the P2Y2/prostaglandin component of cAMP formation, we could assess the indomethacin-insensitive P2 receptor component. Under these conditions, ATP displayed a ten-fold lower potency for stimulation of cAMP formation compared with untreated cells. These data indicate that ATP preferentially activates P2Y2 relative to other P2 receptors in MDCK-D1 cells (P2Y1 and P2Y11, as shown by reverse transcriptase polymerase chain reaction) and that P2Y2 receptor activation is the principal means by which ATP increases cAMP formation in these cells. Blockade of autocrine/paracrine signaling can aid in dissecting the contribution of multiple receptor subtypes activated by an agonist. clonal Madin-Darby canine kidney cells prostaglandin E2 2-methylthioadenosine 5′-triphosphate reverse transcriptase polymerase chain reaction. The identification of multiple receptor subtypes for physiologic agonists can lead to a difficult problem. How can one define the preferred receptor interaction for a physiologic agonist? As an example, a wide variety of cells have been shown to possess receptors for extracellular nucleotides. ATP, which is an important extracellular-signaling molecule, is stored and released from sympathetic neurotransmitter vesicles and from stressed/damaged cells. Receptors that interact specifically with ATP (classified as P2-purinergic receptors) are present in many tissues and cell types (1Fredholm B.B. Abbracchio M.P. Burnstock G. Daly J.W. Harden T.K. Jacobson K.A. Leff P. Williams M. Pharmacol. Rev. 1994; 46: 143-156PubMed Google Scholar, 2Dubyak G.R. El Moatassim C. Am. J. Physiol. 1993; 265: C577-C606Crossref PubMed Google Scholar, 3Burnstock G. Kennedy C. Gen. Pharmacol. 1985; 16: 433-440Crossref PubMed Scopus (1139) Google Scholar, 4Harden T.K. Boyer J.L. Nicholas R.A. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 541-579Crossref PubMed Google Scholar). The P2Y1 and P2Y2 subtypes are two widely expressed G-protein-coupled purinergic receptors that differ in their specificity for nucleotides. P2Y1 receptors bind ATP, and the synthetic agonist 2-methylthio-ATP (MT-ATP),1 whereas P2Y2 receptors respond to both ATP and UTP (2Dubyak G.R. El Moatassim C. Am. J. Physiol. 1993; 265: C577-C606Crossref PubMed Google Scholar, 5Boarder M.R. Weisman G.A. Turner J.T. Wilkinson G.F. Trends Pharmacol. Sci. 1995; 16: 133-139Abstract Full Text PDF PubMed Scopus (184) Google Scholar). Additionally, ATP can be metabolized by ecto-ATPases to adenosine, the agonist for P1-purinergic receptors. We have studied P2 receptor-mediated signaling events in a well differentiated kidney epithelial cell line, Madin-Darby canine kidney (MDCK-D1), derived from distal tubule/collecting duct. P2-purinergic receptors expressed on these cells respond to extracellular nucleotides by increasing the activity of various phospholipases (phospholipases C, D, and A2), the activity of protein kinase C, the concentration of intracellular calcium, the production of cAMP, and transepithelial ion transport (6Firestein B.L. Llopis J. Insel P.A. FASEB J. 1995; 9: A553Google Scholar, 7Balboa M.A. Firestein B.L. Godson C. Bell K.S. Insel P.A. J. Biol. Chem. 1994; 269: 10511-10516Abstract Full Text PDF PubMed Google Scholar, 8Firestein B.L. Xing M. Hughes R.J. Corvera C.U. Insel P.A. Am. J. Physiol. 1996; 271: F610-F618PubMed Google Scholar, 9Xing M. Firestein B.L. Shen G.H. Insel P.A. J. Clin. Invest. 1997; 99: 805-814Crossref PubMed Scopus (76) Google Scholar, 10Post S.R. Jacobson J.P. Insel P.A. J. Biol. Chem. 1996; 271: 2029-2032Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar, 11Simmons N.L. Br. J. Pharmacol. 1981; 73: 379-384Crossref PubMed Scopus (37) Google Scholar, 12Zegarra-Moran O. Romeo G. Galietta L.J. Br. J. Pharmacol. 1995; 114: 1052-1056Crossref PubMed Scopus (55) Google Scholar). In several other cell types, stimulation of P2 receptors decreases intracellular cAMP production via a pertussis toxin-sensitive mechanism (13Munshi R. DeBernardi M.A. Brooker G. Mol. Pharmacol. 1993; 44: 1185-1191PubMed Google Scholar, 14Keppens S. Vandekerckhove A. De Wulf H. Br. J. Pharmacol. 1992; 105: 475-479Crossref PubMed Scopus (50) Google Scholar, 15Okajima F. Tokumitsu Y. Kondo Y. Ui M. J. Biol. Chem. 1987; 262: 13483-13490Abstract Full Text PDF PubMed Google Scholar, 16Yamada M. Hamamori Y. Akita H. Yokoyama M. Circ. Res. 1992; 70: 477-485Crossref PubMed Scopus (54) Google Scholar, 17Valeins H. Merle M. Labouesse J. Mol. Pharmacol. 1992; 42: 1033-1041PubMed Google Scholar, 18Boyer J.L. Lazarowski E.R. Chen X.H. Harden T.K. J. Pharmacol. Exp. Ther. 1993; 267: 1140-1146PubMed Google Scholar). In contrast, ATP was shown to activate adenylyl cyclase in HL60 cells (19Choi S.Y. Kim K.T. Biochem. Pharmacol. 1997; 53: 429-432Crossref PubMed Scopus (25) Google Scholar, 20Jiang L. Foster F.M. Ward P. Tasevski V. Luttrell B.M. Conigrave A.D. Biochem. Biophys. Res. Commun. 1997; 236: 626-630Crossref PubMed Scopus (44) Google Scholar). Using MDCK-D1 cells, we found that P2 receptor agonists increase cAMP production (10Post S.R. Jacobson J.P. Insel P.A. J. Biol. Chem. 1996; 271: 2029-2032Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar) and tested hypotheses regarding several potential mediators for the increase in cAMP production, protein kinase C, Gs, adenosine, and arachidonic acid metabolites. Our results indicated that ATP and UTP, acting at P2-purinergic receptors, increase cAMP via an indomethacin-sensitive pathway, implying that cyclooxygenase-derived products mediate this response. In the current study, we sought to distinguish between the actions of ATP and other nucleotides that act at different P2 receptor subtypes. Our data indicate that P2Y2 receptor-mediated cAMP formation occurs via an indomethacin-sensitive pathway. In contrast, MT-ATP (acting at other classes of receptors, perhaps P2Y1 and/or P2Y11 receptors) preferentially couples to indomethacin-insensitive pathways to increase cAMP production. The physiological agonist ATP increases cAMP via preferential interaction with P2Y2 receptors. MDCK-D1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% serum as described previously (8Firestein B.L. Xing M. Hughes R.J. Corvera C.U. Insel P.A. Am. J. Physiol. 1996; 271: F610-F618PubMed Google Scholar). Cells were used in assays at 60–80% confluency. Basal cAMP levels were increased at cell densities greater than this. Before treatment of cells, growth medium was removed and cells were equilibrated for 30 min at 37 °C in serum-free Dulbecco's modified Eagle's medium containing 20 mm HEPES buffer (DMEH, pH 7.4). Subsequently, cells were incubated in fresh DMEH and various agents as described in the figure legends. Unless otherwise indicated, incubations with agonist were conducted for 5 min at 37 °C in the presence of 200 μmisobutylmethylxanthine, a phosphodiesterase inhibitor, and terminated by aspiration of medium and addition of 7.5% trichloroacetic acid. Trichloroacetic acid extracts were frozen (−20 °C) until assay. Intracellular cAMP levels were determined by radioimmunoassay (Calbiochem) of trichloroacetic acid extracts following acetylation according to the manufacturer's protocol. Production of cAMP was normalized to the amount of acid-insoluble protein assayed by the Bio-Rad protein assay. Cells were treated with indicated concentrations of nucleotide for 5 min in a total volume of 0.5 ml. Incubation medium was removed and assayed for PGE2 content using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI). The amount of PGE2 present in the medium in the absence of nucleotide was subtracted from each point. Total RNA was isolated from MDCK-D1 using Trizol. MDCK-D1 DNA was isolated from cells grown in 150-mm culture dishes. Cells were scraped into ice-cold phosphate-buffered saline, collected by centrifugation (5 min at 500 × g) and resuspended in 5 volumes of digestion buffer (100 mmNaCl2, 10 mm Tris-HCl, 25 mm EDTA, 0.5% SDS, 1 mg/ml proteinase K, pH 8.0). Following overnight incubation at 37 °C, samples were extracted three times with phenol/chloroform/isoamyl alcohol (Ambion) and precipitated with ethanol (2 volumes) and 7.5 m ammonium acetate (0.5 volume). RNA (10 μg) was reverse transcribed in 25 μl of RT buffer (Life Technologies, Inc.) together with 0.002 OD units of random hexamers, 10 mmdithiothreitol, 800 μm dNTP, and 200 units Moloney murine leukemia virus RT. After a 1-h incubation at 37 °C, reactions were stopped by boiling for 4 min and dilution to 100 μl in RNase-free water. To control for possible DNA contamination of the samples, reactions were also performed in the absence of RT enzyme. PCR conditions were identical for all primers (primers: P2y1 forward 5′-ACCCTGTACGGCAGCATCCTSTTCCTCAC-3′, reverse 5′-AGGWAGSAGASGGCGAAGAC-3′ expected product size 422 base pairs; P2y2: forward 5′-AGTCCCCCGTGCTCTACTTT-3′, reverse 5′-GTCAGTCCTGTCCCACCTGT-3′ expected product size 539 base pairs; P2y11: forward 5′-CTGGTGGTTGAGTTCCTGGT-3′, reverse 5′-GTTGCAGGTGAAGAGGAAGC-3′ expected product size 234 base pairs): 10 μl of reverse transcribed RNA or 1 μg of genomic DNA was added to a solution of 20 μm each of forward and reverse primer, 2.5 mm MgCl2buffer (Perkin-Elmer), PCR buffer (50 mm KCl, 10 mm Tris-HCl, pH 8.3), 0.2 mm dNTPs (Amersham Pharmacia Biotech), 5 units of Amplitaq Gold Polymerase (Perkin-Elmer) and dH2O in a total volume of 50 μl. Temperature cycling proceeded as follows: 1 cycle at 95 °C for 10 min to activate the enzyme, 95 °C for 30 s, 60 °C for 90 s and 72 °C for 90 s, for 40 cycles, followed by 72 °C for 10 min. PCR products were then subjected to gel electrophoresis on a 1% Seakem-agarose gel (FMC Bioproducts). The bands were extracted using a Qiaquick gel extraction kit (Qiagen). The DNA was resuspended in Tris-EDTA buffer (10 mm Tris-HCl, 1 mm EDTA, pH 8.0), and 1 volume of the gel-extracted PCR product was purified using a Centricon concentrator (Amicon). Purified fragments were sequenced (ABI automated DNA sequencer, model 377) using the same forward primers that were used to generate the PCR fragments. Chemicals were purchased from the following sources. Forskolin and anti-cAMP antibody from Calbiochem,125I-cAMP from NEN Life Science Products, PGE2immunoassay kit from Cayman Chemical, all other reagents from Sigma. Trizol (Life Technologies, Inc.), Moloney murine leukemia virus reverse transcriptase/5X reaction buffer (Life Technologies, Inc.), DNA polymerization mix (Amersham Pharmacia Biotech), random hexamers (Amersham Pharmacia Biotech), Amplitaq Gold polymerase (Perkin-Elmer), and dNTPs (Amersham Pharmacia Biotech). In previous studies, we showed that extracellular nucleotides that act at P2-purinergic receptors increase cAMP formation in MDCK-D1 kidney epithelial cells (10Post S.R. Jacobson J.P. Insel P.A. J. Biol. Chem. 1996; 271: 2029-2032Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar). The ability of ATP and UTP to stimulate cAMP was inhibited by the cyclooxygenase inhibitor indomethacin, indicating that this response was secondary to the release of arachidonic acid and most likely by its conversion to one or more prostaglandins. Because ATP is generally considered the endogenous ligand for P2-purinergic receptors, our initial assumption was that P2 receptors coupled to adenylyl cyclase activation secondary to the production of prostaglandins. Using indomethacin at a concentration that completely inhibits the ability of exogenous arachidonic acid to stimulate cAMP formation (Fig. 1 A), we found that the increase in cAMP in response to UTP was also abolished (Fig. 1 B). In contrast, the cyclooxygenase inhibitor did not significantly inhibit cAMP formation in response to the P2Y1 receptor agonist MT-ATP. In the presence of 1 μm indomethacin, the ability of ATP to increase cAMP was reduced, but only by ≈80%. These results suggested the involvement of two signaling pathways in coupling P2 receptors to adenylyl cyclase activation: P2Y2 receptors, whose ability to increase cAMP formation appears to be entirely dependent upon the formation of prostaglandin; and another P2Y receptor, whose activation of adenylyl cyclase is apparently independent of prostaglandin production. We sought to determine the identity of the prostaglandins that coupled P2 receptors with adenylyl cyclase activation. MDCK cells produce and release PGE2, prostaglandin I2(prostacyclin), and prostaglandin F2α (21Hassid A. J. Cell. Physiol. 1983; 116: 297-302Crossref PubMed Scopus (17) Google Scholar, 22Weiss B.A. Slivka S.R. Insel P.A. Mol. Pharmacol. 1989; 36: 317-326PubMed Google Scholar). Of these, only PGE2 and prostacyclin, tested using a stable prostacyclin analog (6α-PGI1), were positively coupled to adenylyl cyclase activation (Fig. 2 A) (10Post S.R. Jacobson J.P. Insel P.A. J. Biol. Chem. 1996; 271: 2029-2032Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar, 21Hassid A. J. Cell. Physiol. 1983; 116: 297-302Crossref PubMed Scopus (17) Google Scholar). To correlate prostaglandin production with P2 receptor activation, we measured the PGE2 released following the addition of purinergic receptor agonists. At concentrations that increase cAMP formation, both ATP and UTP substantially increased PGE2release from MDCK cells (EC50 ≈ 30 μm, Fig. 2 B). In contrast, receptor activation with MT-ATP did not increase PGE2 release even at concentrations that maximally stimulated cAMP formation (Figs. 2 B and 4 A). The production of PGE2 was completely blocked by indomethacin (1 μm) pretreatment (data not shown). These data correlate well with the sensitivity of cAMP production to indomethacin for P2Y2 receptor agonists (Fig. 1). Thus, by measuring cAMP formation in MDCK cells pretreated with indomethacin, we could specifically assess activation of indomethacin-insensitive P2Y receptors independent of the contribution of P2Y2 receptor activation.Figure 4Effect of suramin on P2receptor-mediated increase of cAMP in MDCK cells pretreated with indomethacin. A, cells were pretreated with the indicated concentrations of the P2 receptor antagonist suramin for 15 min in the presence of indomethacin (1 μm). Following this preincubation, the indicated concentrations of MT-ATP were added, and incubations continued for 5 min. B, treatments were as in panel Aexcept following pretreatment, cells were stimulated with 100 μm ATP, UTP, MT-ATP, or 3 μm of the prostaglandin precursor arachidonic acid. In each case, data represent the average of three independent experiments.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Having defined conditions that allowed us to distinguish between indomethacin-insensitive and indomethacin-sensitive (P2Y2) receptor activation, we assessed the relative contributions of these two receptor pathways in cAMP accumulation stimulated by the physiological agonist ATP. We compared the ability of ATP to increase cAMP formation via both pathways (i.e. absence of indomethacin) with that of the indomethacin-insensitive pathway alone (i.e. following pretreatment with indomethacin). As shown in Fig. 3 A, pretreatment of cells with indomethacin had no significant effect on the ability of MT-ATP to stimulate cAMP formation (EC50 ≈ 25 μm in each case). In contrast, ATP displayed a substantial difference in its ability to activate adenylyl cyclase following pretreatment of MDCK cells with indomethacin (Fig. 3 B). In untreated cells, ATP, acting via both pathways, displayed an apparent EC50 ≈ 10 μm. However, following indomethacin treatment, ATP, acting selectively via indomethacin-insensitive receptors, demonstrated a greatly reduced potency to increase cAMP (EC50 > 100 μm). This result indicates that in untreated cells, the cAMP formed in response to ATP arises by the preferential activation of P2Y2 receptors. The substantial inhibition of ATP-stimulated cAMP formation by indomethacin suggested that ATP was activating multiple P2receptor pathways, but with greater apparent potency at P2Y2 receptors. Given the previous evidence for expression of P2Y1 and P2Y2 receptors in MDCK-D1 cells (8Firestein B.L. Xing M. Hughes R.J. Corvera C.U. Insel P.A. Am. J. Physiol. 1996; 271: F610-F618PubMed Google Scholar,23Hughes R.J. Rump L.C. Peters L. Firestein B.L. Insel P.A. FASEB J. 1996; 10: A-697Google Scholar) (and the efficacy of MT-ATP in stimulating cAMP formation), we initially hypothesized that the indomethacin-insensitive response to MT-ATP resulted from activation of P2Y1 receptors. To test this assumption, we used suramin as a P2Y1 receptor antagonist. In cells preincubated with indomethacin, suramin competitively inhibited MT-ATP-stimulated cAMP formation (Fig. 4 A) and displayed a pA2 ≈ 5.2 (i.e. an antagonist concentration required to increase EC50 for agonist 2-fold), which closely matches that previously reported for competition at P2Y1 receptors (1Fredholm B.B. Abbracchio M.P. Burnstock G. Daly J.W. Harden T.K. Jacobson K.A. Leff P. Williams M. Pharmacol. Rev. 1994; 46: 143-156PubMed Google Scholar). Suramin also completely inhibited the indomethacin-insensitive component of ATP-stimulated cAMP formation (Fig. 4 B). These data are consistent with the notion that ATP acts at P2Y1receptors to increase cAMP by a prostaglandin-independent pathway. Recently, a new P2Y receptor subtype, P2Y11, which responds to ATP and MT-ATP, was identified and shown to couple to adenylyl cyclase activation (24Communi D. Govaerts C. Parmentier M. Boeynaems J.M. J. Biol. Chem. 1997; 272: 31969-31973Abstract Full Text Full Text PDF PubMed Scopus (312) Google Scholar). However, ATP activated the cloned P2Y11 receptor with much greater potency (EC50= 30 μm) than we observed for the indomethacin-insensitive cAMP response in MDCK cells. Nevertheless, we assessed whether MDCK-D1 cells express this receptor subtype. Indeed, RT-PCR analysis indicated that P2Y1, P2Y2, and P2Y11 receptors are all expressed in MDCK-D1 cells (Fig. 5). PCR of DNA and RT-PCR of RNA yielded bands of the anticipated size for each of the three receptors. Omission of reverse transcriptase from the RT-PCR reaction failed to yield any product indicating the absence of contaminating DNA. The identity of the products (in the case of the P2Y1, the larger of the two products) was confirmed by direct sequencing using the forward primer. Thus, although the pharmacology of the indomethacin-insensitive cAMP response is consistent with that of a P2Y1 receptor, we cannot exclude the possible contribution of P2Y11receptors in mediating the indomethacin-insensitive response to ATP. Previous studies have demonstrated the ability of P2receptor agonists to regulate transepithelial ion transport in MDCK cells (11Simmons N.L. Br. J. Pharmacol. 1981; 73: 379-384Crossref PubMed Scopus (37) Google Scholar, 12Zegarra-Moran O. Romeo G. Galietta L.J. Br. J. Pharmacol. 1995; 114: 1052-1056Crossref PubMed Scopus (55) Google Scholar). PGE2 and other agents that increase cAMP are known to couple receptors to ion transport in epithelial cells. In MDCK cells, the ability of P2Y2, but not P2Y1, receptor agonists to elicit ion transport was indomethacin-sensitive (12Zegarra-Moran O. Romeo G. Galietta L.J. Br. J. Pharmacol. 1995; 114: 1052-1056Crossref PubMed Scopus (55) Google Scholar). Similarly, the ability of exogenous arachidonic acid to alter ion transport was inhibited by indomethacin. The results that demonstrate the indomethacin-sensitive cAMP production elicited by P2Y2agonists provide the most likely molecular basis for the ability of these receptors to couple to ion transport. Moreover, our finding that MDCK cells also express P2Y11 receptors raises the possibility that this receptor subtype may regulate ion transport via activation of adenylyl cyclase. In MDCK-D1 cells, cAMP is a messenger that is considerably “downstream” from the initial occupancy by agonist of the P2Y2 receptors. Nucleotide-mediated stimulation of cAMP formation requires receptor occupancy, activation of cyclic phospholipase A2 (via apparent involvement of Ca2+ and multiple protein kinase C isoforms (see Ref. 9Xing M. Firestein B.L. Shen G.H. Insel P.A. J. Clin. Invest. 1997; 99: 805-814Crossref PubMed Scopus (76) Google Scholar), cyclooxygenase-mediated formation of PGE2, PGE2release from cells and autocrine/paracrine activation of PGE2 receptors, Gs, and adenylyl cyclase). Thus, indomethacin, an inhibitor of an intermediate step in this scheme, can be used to define the relative ability of ATP to act at P2Y2 receptors in MCDK-D1 cells. Inhibitors that act on other components of the signaling pathways, which are not shared by the different P2-purinergic receptors, might also be used in this manner. We predict that selective inhibitors of the receptors that couple prostaglandin binding to activation of adenylyl cyclase (presumably EP2 receptors) (25Coleman R.A. Smith W.L. Narumiya S. Pharmacol. Rev. 1994; 46: 205-229PubMed Google Scholar) should also distinguish the indomethacin-sensitive (P2Y2) and indomethacin-insensitive components of ATP action. The existence of multiple subtypes appears to be very common for G-protein-coupled receptors. Pharmacological approaches that involve use of receptor-selective agonists and antagonists have not kept pace with the discovery of receptor subtypes by molecular cloning strategies. In the case of P2-purinergic receptors, the absence of high affinity antagonists and the limited specificity of agonists have made it difficult to define precisely the cellular function of different receptor subtypes (4Harden T.K. Boyer J.L. Nicholas R.A. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 541-579Crossref PubMed Google Scholar). In many cases receptor subtypes that recognize the same physiologic agonist preferentially activate different signaling pathways. In addition to the P2-purinergic receptors and the physiologic agonist ATP, other examples include receptors for adenosine, norepinephrine/epinephrine, dopamine, acetylcholine (muscarinic receptors), histamine, prostaglandins, and serotonin as well as receptor for certain peptides and peptide hormones (e.g.angiotensin and vasopressin) (26Alexander S.P.H. Peters J.A. Babbedge R. Trends in Pharmacological Science Receptor and Ion Channel Supplement. Eighth Ed. Elsevier Trends Journals, Cambridge1997: 1-75Google Scholar). Most work to date has emphasized linkage to different classes of G-proteins as the explanation for differences in signaling. The current studies show that one can use blockade of downstream signals that result from differences in signaling cascades to define contribution of different receptor subtypes that recognize the same physiologic agonist. Such downstream differences may prove useful for the analysis of other receptor systems, in particular those for which response has been attributed, at least in part, to generation of cyclooxygenase-derived products (e.g. see Refs. 27Marathe G.K. Yousufzai S.Y. Abdel-Latif A.A. Biochem. Pharmacol. 1996; 52: 1261-1269Crossref PubMed Scopus (7) Google Scholar, 28Esqueda E.E. Gerstin Jr., E.H. Griffin M.T. Ehlert F.J. Biochem. Pharmacol. 1996; 52: 643-658Crossref PubMed Scopus (36) Google Scholar, 29Bareis D.L. Manganiello V.C. Hirata F. Vaughan M. Axelrod J. Proc. Natl. Acad. Sci. U. S. A. 1983; 80: 2514-2518Crossref PubMed Scopus (74) Google Scholar, 30Partington C.R. Edwards M.W. Daly J.W. Proc. Natl. Acad. Sci. U. S. A. 1980; 77: 3024-3028Crossref PubMed Scopus (67) Google Scholar)." @default.
• W2086659384 created "2016-06-24" @default.
• W2086659384 creator A5026164472 @default.
• W2086659384 creator A5040940806 @default.
• W2086659384 creator A5043890836 @default.
• W2086659384 creator A5044712179 @default.
• W2086659384 creator A5055677266 @default.
• W2086659384 creator A5057877905 @default.
• W2086659384 creator A5068721240 @default.
• W2086659384 creator A5081338208 @default.
• W2086659384 date "1998-09-01" @default.
• W2086659384 modified "2023-10-01" @default.
• W2086659384 title "ATP Activates cAMP Production via Multiple Purinergic Receptors in MDCK-D1 Epithelial Cells" @default.
• W2086659384 cites W1514596093 @default.
• W2086659384 cites W1623800398 @default.
• W2086659384 cites W1815757713 @default.
• W2086659384 cites W1981183509 @default.
• W2086659384 cites W1981215615 @default.
• W2086659384 cites W1985211628 @default.
• W2086659384 cites W2000601219 @default.
• W2086659384 cites W2017987525 @default.
• W2086659384 cites W2026398072 @default.
• W2086659384 cites W2032296752 @default.
• W2086659384 cites W2033536877 @default.
• W2086659384 cites W2048939907 @default.
• W2086659384 cites W2069982768 @default.
• W2086659384 cites W2071554154 @default.
• W2086659384 cites W2074864029 @default.
• W2086659384 cites W2078323484 @default.
• W2086659384 cites W2087695583 @default.
• W2086659384 cites W2090429326 @default.
• W2086659384 cites W2104234386 @default.
• W2086659384 cites W2160082093 @default.
• W2086659384 doi "https://doi.org/10.1074/jbc.273.36.23093" @default.
• W2086659384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9722536" @default.
• W2086659384 hasPublicationYear "1998" @default.
• W2086659384 type Work @default.
• W2086659384 sameAs 2086659384 @default.
• W2086659384 citedByCount "72" @default.
• W2086659384 countsByYear W20866593842012 @default.
• W2086659384 countsByYear W20866593842013 @default.
• W2086659384 countsByYear W20866593842015 @default.
• W2086659384 countsByYear W20866593842016 @default.
• W2086659384 countsByYear W20866593842017 @default.
• W2086659384 countsByYear W20866593842019 @default.
• W2086659384 countsByYear W20866593842020 @default.
• W2086659384 countsByYear W20866593842021 @default.
• W2086659384 countsByYear W20866593842023 @default.
• W2086659384 crossrefType "journal-article" @default.
• W2086659384 hasAuthorship W2086659384A5026164472 @default.
• W2086659384 hasAuthorship W2086659384A5040940806 @default.
• W2086659384 hasAuthorship W2086659384A5043890836 @default.
• W2086659384 hasAuthorship W2086659384A5044712179 @default.
• W2086659384 hasAuthorship W2086659384A5055677266 @default.
• W2086659384 hasAuthorship W2086659384A5057877905 @default.
• W2086659384 hasAuthorship W2086659384A5068721240 @default.
• W2086659384 hasAuthorship W2086659384A5081338208 @default.
• W2086659384 hasBestOaLocation W20866593841 @default.
• W2086659384 hasConcept C160225129 @default.
• W2086659384 hasConcept C170493617 @default.
• W2086659384 hasConcept C172590197 @default.
• W2086659384 hasConcept C185592680 @default.
• W2086659384 hasConcept C2778938600 @default.
• W2086659384 hasConcept C55493867 @default.
• W2086659384 hasConcept C57306754 @default.
• W2086659384 hasConcept C67907053 @default.
• W2086659384 hasConcept C86803240 @default.
• W2086659384 hasConcept C95444343 @default.
• W2086659384 hasConceptScore W2086659384C160225129 @default.
• W2086659384 hasConceptScore W2086659384C170493617 @default.
• W2086659384 hasConceptScore W2086659384C172590197 @default.
• W2086659384 hasConceptScore W2086659384C185592680 @default.
• W2086659384 hasConceptScore W2086659384C2778938600 @default.
• W2086659384 hasConceptScore W2086659384C55493867 @default.
• W2086659384 hasConceptScore W2086659384C57306754 @default.
• W2086659384 hasConceptScore W2086659384C67907053 @default.
• W2086659384 hasConceptScore W2086659384C86803240 @default.
• W2086659384 hasConceptScore W2086659384C95444343 @default.
• W2086659384 hasIssue "36" @default.
• W2086659384 hasLocation W20866593841 @default.
• W2086659384 hasOpenAccess W2086659384 @default.
• W2086659384 hasPrimaryLocation W20866593841 @default.
• W2086659384 hasRelatedWork W141077555 @default.
• W2086659384 hasRelatedWork W2051912179 @default.
• W2086659384 hasRelatedWork W2108988197 @default.
• W2086659384 hasRelatedWork W2120437215 @default.
• W2086659384 hasRelatedWork W2124436106 @default.
• W2086659384 hasRelatedWork W2170784049 @default.
• W2086659384 hasRelatedWork W2379909826 @default.
• W2086659384 hasRelatedWork W2982255901 @default.
• W2086659384 hasRelatedWork W2997898741 @default.
• W2086659384 hasRelatedWork W4220682010 @default.
• W2086659384 hasVolume "273" @default.
• W2086659384 isParatext "false" @default.
• W2086659384 isRetracted "false" @default.
• W2086659384 magId "2086659384" @default.
• W2086659384 workType "article" @default.